Overview

Barrett's Esophagus - 315 - 3 Way Cross-Over

Status:
Completed

Trial end date:
2003-04-01

Target enrollment:

Participant gender:

Summary

This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Esomeprazole